CVS Health

CVS Health Corporation is the largest US pharmacy chain by revenue and one of the largest US healthcare companies — combining retail pharmacy (~9,000 locations across 50 states), the Caremark pharmacy-benefit-manager (PBM, the second-largest US PBM behind Express Scripts/Cigna), the Aetna health-insurance subsidiary (acquired 2018 for $69 billion), and the MinuteClinic retail-clinic operation. CVS Health trades on NYSE as CVS. The company employs approximately 300,000 US workers. The 2024 announcement of an operational restructuring under CEO David Joyner signaled the company's strategic focus on integration of pharmacy, PBM, and health-insurance economics.

CVS Health's segments operate at vastly different scales. Aetna serves approximately 39 million medical-insurance members across commercial, Medicare, and Medicaid lines. Caremark processes approximately 2 billion annual prescriptions. Retail pharmacy fills approximately 1 billion+ prescriptions annually. MinuteClinic operates approximately 1,100 retail clinics, plus the Oak Street Health value-based primary-care clinics (acquired 2023 for $10.6 billion) and Signify Health home-health platform (acquired 2022 for $8 billion).

CVS Health's AI strategy spans pharmacy operations, retail-clinic care, and Aetna underwriting. Pharmacy automation (script-filling robotics, AI-augmented dispensing, AI clinical-decision support via Wolters Kluwer Lexicomp and First Databank) is widely deployed. Caremark uses AI extensively for prior-authorization decisioning (which has been the subject of regulatory scrutiny), formulary management, and member-engagement. Aetna applies AI to underwriting, fraud detection, and member-engagement automation. MinuteClinic clinics use AI ambient documentation (partnerships with Abridge, Suki, and Microsoft Nuance DAX) to reduce clinician documentation burden. The acquired Oak Street Health and Signify Health businesses both rely heavily on AI-augmented care-management workflows. The company faces ongoing pressure from the proposed FTC investigation of PBM practices (with AI-driven decision-making at the center of regulatory scrutiny).